Celltrion is continuing to spearhead global competition to Genentech/Novartis’s Xolair (omalizumab), now picking up an approval from the UK’s Medicines and Healthcare products Regulatory Agency for its Omlyclo biosimilar treatment for allergic asthma and chronic rhinosinusitis with nasal polyps.
Celltrion’s Xolair Biosimilar Reaches UK, Following Key US Filing
Korean Firm Obtained Pan-European Marketing Authorization For Omalizumab In May
Celltrion has ticked off another major regulator as it continues to lead the pack of global developers for biosimilar Xolair.
